Characteristic |
Everolimus 5 mg/day (n = 12) |
Everolimus 10 mg/day (n = 12) |
---|---|---|
Median (range) age, y | 55 (27-75) | 56 (32-75) |
Sex, n (%) | ||
Male | 5 (41.7) | 4 (33.3) |
Female | 7 (58.3) | 8 (66.7) |
WHO performance status, n (%) | ||
0 | 3 (25.0) | 1 (8.3) |
1 | 9 (75.0) | 9 (75.0) |
2 | 0 | 2 (16.7) |
Prior antineoplastic therapy, n (%) | ||
Surgery | 11 (91.7) | 10 (83.3) |
Radiotherapy | 3 (25.0) | 3 (25.0) |
Chemotherapy | 10 (83.3) | 10 (83.3) |
Targeted therapy | 5 (41.7) | 5 (41.7) |
Immunotherapy | 3 (25.0) | 2 (16.7) |
Hormonal therapy | 2 (16.7) | 0 |